Stifel stays Buy on Oruka Therapeutics (ORKA) after Ph2a data from EVERLAST-A study
Tweet Send to a Friend
Stifel analyst Alex Thompson reiterated a Buy rating and $72.00 price target on Oruka Therapeutics (NASDAQ: ORKA)The analyst commented, "2Q26 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
